Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Can B Corp CANB

Can B Corp. is a health and wellness company. The Company is engaged in developing, manufacturing, and selling products containing cannabinoids derived from hemp biomass and the licensing of durable medical devices. Its products include oils, creams, moisturizers, isolates, gel caps, spa products, and concentrates and lifestyle products. It develops its own line of proprietary products, as well as seeks synergistic value through acquisitions in the hemp industry. Its Duramed Division provides a sam Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients' needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient, who signs a rental form, for a 35-day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The Company is also focuses on protecting and commercializing the cannabis patents covering liquid formulations of cannabis.


OTCQB:CANB - Post by User

<< Previous
Bullboard Posts
Next >>
Post by AveragePennyon Sep 03, 2021 11:25am
119 Views
Post# 33809271

Can B Corp Reports 96% YoY Revenue Growth

Can B Corp Reports 96% YoY Revenue Growth

Resumption and surge of elective surgeries impacted revenue.

For the six months ending June 30, 2021, revenue was $0.7 million, which is a 9% decline compared to $0.8 million in Q2 2020. Can B saw a rebound and revenue increase in Q2 2021 compared to prior periods because of the surge and resumption of elective surgeries. Gross profit was $0.4 million, dropping by $0.2 million from a year ago with a gross margin of 52.7%. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.

https://ih.advfn.com/stock-market/USOTC/can-b-qb-CANB/stock-news/85981033/canb-can-b-corp-reports-96-yoy-revenue-growth-i

<< Previous
Bullboard Posts
Next >>